{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:02:19Z","timestamp":1790186539513,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.contraception.2011.05.013","type":"journal-article","created":{"date-parts":[[2011,7,14]],"date-time":"2011-07-14T04:47:14Z","timestamp":1310618834000},"page":"42-50","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study"],"prefix":"10.1016","volume":"85","author":[{"suffix":"Sr","given":"Stephan","family":"Bart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Marr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstanze","family":"Diefenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Trummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole","family":"Sampson-Landers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2011.05.013_bb0005","first-page":"313","article-title":"Spina bifida and other neural tube defects","volume":"30","author":"Northrup","year":"2000","journal-title":"Curr Probl Pediatr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0010","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1741-4520.2006.00104.x","article-title":"Etiology, pathogenesis and prevention of neural tube defects","volume":"46","author":"Padmanabhan","year":"2006","journal-title":"Congenit Anom (Kyoto)"},{"key":"10.1016\/j.contraception.2011.05.013_bb0015","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJM199911113412006","article-title":"Neural-tube defects","volume":"341","author":"Botto","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.05.013_bb0020","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1016\/S0140-6736(01)07104-5","article-title":"Quantifying the effect of folic acid","volume":"358","author":"Wald","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.013_bb0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(06)68582-6","article-title":"Folic acid: a public-health challenge","volume":"367","author":"Eichholzer","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.013_bb0030","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1001\/jama.1995.03530210052030","article-title":"Folate levels and neural tube defects. Implications for prevention","volume":"274","author":"Daly","year":"1995","journal-title":"JAMA"},{"key":"10.1016\/j.contraception.2011.05.013_bb0035","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0140-6736(91)90133-A","article-title":"Prevention of neural tube defects: results of the Medical Research Council Vitamin Study","volume":"338","year":"1991","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.013_bb0040","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJM199212243272602","article-title":"Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation","volume":"327","author":"Czeizel","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.05.013_bb0045","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(80)90886-7","article-title":"Possible prevention of neural-tube defects by periconceptional vitamin supplementation","volume":"1","author":"Smithells","year":"1980","journal-title":"Lancet"},{"key":"10.1016\/j.contraception.2011.05.013_bb0050","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199911113412001","article-title":"Prevention of neural-tube defects with folic acid in China. China\u2013U.S. Collaborative Project for Neural Tube Defect Prevention","volume":"341","author":"Berry","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.contraception.2011.05.013_bb0055","first-page":"1409","article-title":"Racial\/ethnic differences in the birth prevalence of spina bifida \u2014 United States, 1995\u20132005","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2009","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2011.05.013_bb0060","first-page":"9","article-title":"Spina bifida and anencephaly prevalence \u2014 United States, 1991\u20132001","volume":"51","author":"Mathews","year":"2002","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.contraception.2011.05.013_bb0065","author":"Mathews"},{"key":"10.1016\/j.contraception.2011.05.013_bb0070","doi-asserted-by":"crossref","first-page":"626","DOI":"10.7326\/0003-4819-150-9-200905050-00009","article-title":"Folic acid for the prevention of neural tube defects: U.S. Preventive Services Task Force recommendation statement","volume":"150","author":"Preventive Services Task Force","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.contraception.2011.05.013_bb0075","first-page":"5","article-title":"Use of supplements containing folic acid among women of childbearing age \u2014 United States, 2007","volume":"57","author":"Centers for Disease Control and Prevention (CDC)","year":"2008","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2011.05.013_bb0080","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.whi.2009.10.001","article-title":"Folic acid supplementation in younger and older nonpregnant women of reproductive age: findings from the Central Pennsylvania Women's Health Study (CePAWHS)","volume":"20","author":"Evans","year":"2010","journal-title":"Womens Health Issues"},{"key":"10.1016\/j.contraception.2011.05.013_bb0085","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.amepre.2010.01.025","article-title":"Folic acid intake among U.S. women aged 15\u201344 years, National Health and Nutrition Examination Survey, 2003\u20132006","volume":"38","author":"Tinker","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.contraception.2011.05.013_bb0090","author":"Food & Drug Administration"},{"key":"10.1016\/j.contraception.2011.05.013_bb0095","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.gyobfe.2004.12.004","article-title":"Pregnancies occurring during oral contraception: lessons from the GRECO study","volume":"34","author":"Barjot","year":"2006","journal-title":"Gynecol Obstet Fertil"},{"key":"10.1016\/j.contraception.2011.05.013_bb0100","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/AOG.0b013e3181b46f54","article-title":"Rate of pregnancy after using drospirenone and other progestin-containing oral contraceptives","volume":"114","author":"Cronin","year":"2009","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.05.013_bb0105","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00005721-200507000-00002","article-title":"Folic acid fortification: should oral contraceptives be next?","volume":"30","author":"Verbiest","year":"2005","journal-title":"MCN Am J Matern Child Nurs"},{"key":"10.1016\/j.contraception.2011.05.013_bb0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2307\/2991665","article-title":"Compliance, counseling and satisfaction with oral contraceptives: a prospective evaluation","volume":"30","author":"Rosenberg","year":"1998","journal-title":"Fam Plann Perspect"},{"key":"10.1016\/j.contraception.2011.05.013_bb0115","unstructured":"Data on file, Bayer HealthCare Pharmaceuticals. Clinical study report number A27410 (protocol number 309662). 30 Jun 2008."},{"key":"10.1016\/j.contraception.2011.05.013_bb0120","unstructured":"Data on file, Bayer HealthCare Pharmaceuticals. Clinical study report number A28575 (protocol number 309664). 10 Nov 2008."},{"key":"10.1016\/j.contraception.2011.05.013_bb0125","first-page":"157","article-title":"Changes in folate levels following cessation of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg co-administration","volume":"15","author":"Diefenbach","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.05.013_bb0130","first-page":"158","article-title":"Changes in folate levels following a 24-week co-administration of Yasmin and levomefolate calcium 0.451 mg or folic acid 400 mcg","volume":"15","author":"Diefenbach","year":"2010","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2011.05.013_bb0135","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ajcn\/71.4.962","article-title":"Plasma total homocysteine, pregnancy complications, and adverse pregnancy outcomes: the Hordaland Homocysteine study","volume":"71","author":"Vollset","year":"2000","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0140","doi-asserted-by":"crossref","first-page":"44S","DOI":"10.1097\/00006250-200604001-00104","article-title":"A new tool for assessing the folate status of reproductive-aged urban Latina women","volume":"107","author":"Casta\u00f1o","year":"2006","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.contraception.2011.05.013_bb0145","first-page":"362","article-title":"Spina bifida and anencephaly before and after folic acid mandate \u2014 United States, 1995\u20131996 and 1999\u20132000","volume":"53","author":"Centers for Disease Control and Prevention (CDC)","year":"2004","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.contraception.2011.05.013_bb0150","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/ajcn\/79.3.473","article-title":"Supplementation with [6S]-5-methyltetrahydrofolate or folic acid equally reduces plasma total homocysteine concentrations in healthy women","volume":"79","author":"Lamers","year":"2004","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0155","first-page":"3353","article-title":"Increases in blood folate indices are similar in women of childbearing age supplemented with [6S]-5-methyltetrahydrofolate and folic acid","volume":"132","author":"Venn","year":"2002","journal-title":"J\u00a0Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0160","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1093\/ajcn\/86.5.1414","article-title":"Calculation of red blood cell folate steady state conditions and elimination kinetics after daily supplementation with various folate forms and doses in women of childbearing age","volume":"86","author":"Pietrzik","year":"2007","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0165","unstructured":"Data on file, Bayer HealthCare Pharmaceuticals. Clinical study report number A43598 (protocol number 310662). 2 Jul 2009."},{"key":"10.1016\/j.contraception.2011.05.013_bb0170","series-title":"Guide to Clinical Preventive Services","first-page":"467","article-title":"Screening for neural tube defects \u2014 including folic acid\/folate prophylaxis","author":"Preventive Services Task Force","year":"1996"},{"key":"10.1016\/j.contraception.2011.05.013_bb0175","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/ajcn\/84.1.156","article-title":"Red blood cell folate concentrations increase more after supplementation with [6S]-5-methyltetrahydrofolate than with folic acid in women of childbearing age","volume":"84","author":"Lamers","year":"2006","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0180","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/ajcn\/77.3.658","article-title":"Comparison of the effect of low-dose supplementation with L-5-methyltetrahydrofolate or folic acid on plasma homocysteine: a randomized placebo-controlled study","volume":"77","author":"Venn","year":"2003","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0185","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/jn\/134.3.580","article-title":"The short-term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men","volume":"134","author":"Pentieva","year":"2004","journal-title":"J Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0190","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1093\/jn\/129.4.913","article-title":"Availability of food folate in humans","volume":"129","author":"Prinz-Langenohl","year":"1999","journal-title":"J Nutr"},{"key":"10.1016\/j.contraception.2011.05.013_bb0195","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.contraception.2009.03.013","article-title":"Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24\/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21\/7 combined oral contraceptive","volume":"80","author":"Anttila","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.013_bb0200","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.013_bb0205","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.contraception.2009.01.016","article-title":"Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24\/4-day regimen","volume":"80","author":"Hernadi","year":"2009","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2011.05.013_bb0210","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/AOG.0b013e318187e1c5","article-title":"Treatment of acne using a 3-milligram drospirenone\/20-microgram ethinyl estradiol oral contraceptive administered in a 24\/4 regimen: a randomized controlled trial","volume":"112","author":"Maloney","year":"2008","journal-title":"Obstet Gynecol"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411002460?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782411002460?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T17:17:52Z","timestamp":1790183872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782411002460"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0010782411002460"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2011.05.013","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2011.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}